drug · small molecule
patient view →repotrectinib
Marketedupdated 2mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
indications
investigational
NSCLC
targets
NT-3 growth factor receptorBDNF/NT-3 growth factors receptorCD74-ROS1High affinity nerve growth factor receptorProto-oncogene tyrosine-protein kinase ROS
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that